Please login to the form below

Not currently logged in
Email:
Password:

LJPC-501

This page shows the latest LJPC-501 news and features for those working in and with pharma, biotech and healthcare.

La Jolla plans filing on back of blood pressure trial data

La Jolla plans filing on back of blood pressure trial data

The ATHOS-3 study found that LJPC-501, a synthetic formulation of natural peptide called angiotensin II that regulates blood pressure, hit its primary endpoint of raising blood pressure in patients ... All told, 70% of the LJPC-501-treated group in

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics